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Abstract 
Introduction  
A nonfatal overdose due to opioids can be viewed as a failure to adequately treat addiction or as an 
opportunity to start or improve treatment for opioid use disorder (OUD).  It is important to determine 
how patients are being treated before and after an overdose. Primary care providers are at the forefront 
of the opioid epidemic and have the potential to influence opioid prescribing habits and treatment of 
OUD. Evaluation of the opioid epidemic leading to potential solutions has significant public health 
relevance.  
Objective 
To determine treatment utilization before and after nonfatal overdoses. 
Methods 
We conducted a longitudinal retrospective cohort study of Pennsylvania Medicaid patients aged 12-64 
with a nonfatal opioid or heroin overdose event between 2008-2013. We measured unduplicated 
patient-level univariate descriptive statistics for demographic and treatment utilization 6 months before 
and 6 months after an overdose. We identified inpatient, outpatient, and pharmacy claims data from 
Pennsylvania’s managed care and fee-for-service Medicaid programs. We excluded Non-Pennsylvania 
residents, those dually-eligible for Medicare, age < 12 or age > 64, and non-opioid or non-heroin 
overdoses for a total of 7,690 enrollees. We evaluated the following demographic factors: age, gender, 
v 
and race. The main outcome measure was OUD medication-assisted treatment (MAT) utilization: 
methadone, buprenorphine, and naltrexone. Secondary outcome measures included the length (days) 
supply of prescription opioids pre and post-overdose.  
Results 
Among 3,009 enrollees who had a heroin overdose and 4,989 who had a prescription opioid overdose, 
most were <40 years old and white. Among those who survived after the non-fatal overdose, opioid use 
did not change in the heroin group (40.6% pre and 39.7% post, P = 0.12).  Whereas enrollees in the 
opioid group were less likely to fill opioid prescriptions post-overdose (65.4% to 59.6% p < 0.001). 
Likewise, the percent of enrollees with >90 days duration of opioids did not change in the heroin group 
pre- to post-overdose (9.4% to 9.0%, P =0.07) but decreased in the opioid group (32.2% to 28.3%, P < 
0.001). MAT increased after overdose in the heroin (28.7% to 33.0%, P < 0.001) and opioid group (from 
13.6% to 15.1%, P = 0.001).  
Conclusions 
Overall, we saw similar OUD medication and treatment utilization rates before and after overdose 
events. These findings are concerning because they show a lack of addiction treatment escalation after 
an overdose.  
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Background 
Morbidity and mortality due to opioids are one of the biggest public health issues affecting Americans 
today. In 2015 alone, there were 20,101 overdose deaths related to prescription opioid medications, 
and 12,990 overdose deaths related to heroin.1 This represents at 2.8-fold increase in the total number 
of deaths involving opioids since 2002.2 The Centers for Disease Control and Prevention (CDC) and The 
White House have publicly stated that the effects of opioids have reached epidemic proportions.1,3 
There are no boundaries for the crippling reach of opioids, which have impacted every state in the 
nation and every demographic. Rates of opioid overdose deaths are also on the rise globally, which has 
raised concerns about a potential worldwide opioid pandemic.4 This epidemic has been building for 
decades and it will take a coordinated systems approach to change the course of the crisis.  
Opioids are a class of pain relieving medications that include the illicit drug heroin as well as the 
prescription medications oxycodone, hydrocodone, codeine, morphine and fentanyl. Virtually everyone 
experiences moderate or severe pain at some point in their lifetime. More than 30% of Americans have 
some form of chronic pain5,6, so it is unsurprising that opioids are the third most commonly prescribed 
class of medications in the United States behind antimicrobials and antidepressant.7 In 2012 alone, 259 
million opioid prescriptions were written in the US, which is more than enough to give every American 
adult their own bottle of pills.2 The same year, 6.9% of adults aged 20 and over (approximately 19 
million Americans) reported using a prescription opioid analgesic in the past 30 days.8 In 2016, a 
staggering 12% of Americans had a prescription for opioids.9-11 Fortunately, progress has been made in 
reducing opioid prescriptions. 
Since the height of opioid prescribing in 2012, there has been a 12% decrease in opioid prescriptions in 
the last three years.12 This decrease equates to nearly 17 million fewer filled prescriptions in 2015 
alone.12 Declines were seen in every state in the country except for South Dakota .12 The US Drug 
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Enforcement Administration (DEA) finalized an order to reduce production quotas for a variety of 
Schedule II medications which include opioids by 25%.13 Despite this decrease, opioid overdose deaths 
continue to reach new highs.1 The increase in overdose death, despite nationwide decreases in opioid 
prescriptions could signal a paradigm shift to people using illicit drugs like heroin. A constellation of 
factors came together in the previous few decades to trigger the cascade of opioid prescriptions and 
subsequent overdoses.  
Although opioids have been present in America for centuries, it wasn’t until the 1990s that opioid use 
began to accelerate rapidly due to several factors. Low-quality, but influential studies published in the 
1980s reported a minimal risk of addiction in patients using opioids.14,15 Another article published in 
1990 reiterated the widespread belief that “therapeutic use of opiate analgesics rarely results in 
addiction”.16 Relief of pain is one of the fundamental obligations of medical professionals; decreasing 
patient’s pain while not increasing their addiction risk was highly influential on prescribing patterns. 
These studies and the growing pharmaceutical industry led to the trend in the liberalization of the use of 
opioids for the treatment of pain.  
Pharmaceutical influence peaked in 1996 with the release of OxyContin by Purdue Pharmaceuticals, a 
more addiction-prone formulation of oxycodone. By 2004, OxyContin had become the most prevalent 
prescription opioid abused in the United States.17 In 2015 approximately 1,000 overdose deaths were 
attributed to OxyContin.18 Soon after the introduction of OxyContin, the Joint Commission embraced the 
concept of “Pain as the 5th Vital Sign” and penned a report sponsored by Purdue Pharmaceuticals (the 
makers of OxyContin) stating that some clinicians have inaccurate and exaggerated concerns about the 
addiction risk of opioids.19  
Welfare and health care reform in the 1990’s also played a role in the overreliance on opioids.20 
Managed care organizations recognized that opioids were less expensive than comprehensive pain 
3 
management clinics and therefore stopped reimbursement for those services.5 Payers were unwilling to 
cover non-pharmacological interventions, leaving opioids as one of the few therapeutic options. The 
embrace of opioids by the scientific community in part due to these highly influential factors lead to 
changes in physician prescribing practices causing a surge in opioid prescriptions.21  
This rise in prescriptions correlated with a rapid increase in opioid-related morbidity and mortality due 
to their intrinsic addictive properties.22 Medical providers need to ensure that patients’ pain is properly 
assessed and managed; however, that obligation needs to be balanced with the responsibility of not 
limiting the exposure to risk of addiction. It was difficult to predict the far-reaching downstream effects 
of these medications that would eventually lead to an epidemic of overdose.  
Opioid medications exert their analgesic effect by primarily binding to mu-opioid receptors in the brain. 
When opioids attach to these receptors, they reduce the perception of pain and produce a sense of 
euphoria, leading to positive reinforcement. An innate and hazardous property of opioids is their 
tendency, especially when used repeatedly over time, to induce tolerance. Tolerance occurs when the 
person no longer responds to the drug as strongly as they did at first, thus necessitating a higher dose to 
achieve the same effect.  This tolerance contributes to the risk of addiction and overdose. Some opioids 
show tolerance after a single dose.23 In addition, drug dependence or susceptibility to withdrawal 
symptoms is another clinically important consequence of repeated exposure to escalating dosages of 
opioids. The question of why some people develop addiction to these inherently addictive medications 
while others do not is not clear. 
Addiction is the end-result of neurochemical changes to the brain that create compulsive drug seeking 
and drug use behavior. Because of opioids effect on the part of the brain that regulates breathing, 
excessive use of opioids can cause respiratory depression leading to overdose death. Addiction and 
overdose can occur in individuals with valid prescriptions for opioids to relieve pain and in nonmedical 
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users (i.e., using medications that were not prescribed for them or were taken only for the experience or 
feeling that they caused). Almost 75% of all opioid misuse starts with people taking medication that was 
not prescribed for them.24 A study involving 136,000 opioid overdose patients treated in the emergency 
department in 2010, found that only 13% of those patients had a chronic pain diagnosis.25  Predictors of 
overdose have been identified in the literature that can allow health care providers to targeted 
interventions for those at risk.26-28  
Risk Factors 
Several risk factors contribute to overdose including prior overdose events, obtaining overlapping 
prescriptions from multiple providers and pharmacies, taking high daily dosages of prescription opioids, 
having mental illness or a history of alcohol or other substance abuse, and living in rural areas and 
having low income.29 A prior overdose is the biggest risk factor for a future overdose.30 Higher dosages 
were associated with an increased risk of overdose compared to lower dosages (1 to < 20 MME/day).31 
Extended-release (ER) and Long-acting (LA) opioids were also associated with an increased overdose risk 
compared with short-acting opioids. Having overlapping prescriptions was also strongly associated with 
increased risk of overdose.32-33 Overdose risk also increases with the concomitant use of certain other 
medications including muscle relaxants and benzodiazepines.34  
Muscle relaxants, in addition to opioids and benzodiazepines compose the “triple threat” of overdose. 
When combined, these medications are synergistic in their potential to cause respiratory depression 
increasing the risk of death. It is well known that opioid overdoses often involve more than one of these 
medications. Opioid users often use muscle relaxants and benzodiazepines to augment the effect of 
euphoria. In opioid users, combining the effects of benzodiazepines enhances the positive subjective 
effects of opioids.35  
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Turner and Liang found that overdose risk increased with increasing duration of benzodiazepine 
treatment.36-37 Use of ≥ 4 pharmacies or prescribers in the past year was both associated with an 
increased overdose risk.38 Opioid-related deaths are higher in rural areas even after adjusting for 
population density.39 White patients have almost twice the overdose rate as black patients.40 Inequity in 
pain management with more restrictive use of opioids for black patients compared to white patients can 
partly explain these racial differences.41-43 Substance use disorder diagnoses including opioid use 
disorder (OUD) were associated with an increased risk of overdose.  
OUD is the problematic pattern of opioid use leading to clinically significant impairment or stress.44 
Symptoms of OUD include a strong desire for opioids, inability to control or reduce use, and 
development of tolerance. This primary, chronic, and relapsing brain disorder currently affects 2.5 
million Americans and continues to affect more every year.45,4 Even with treatment, the underlying 
vulnerability to addiction never disappears. The chronicity and relapsing nature of OUD are like other 
chronic conditions that are difficult to treat (e.g., hypertension and diabetes). OUD has penetrated every 
societal demographic including race, socioeconomic status, and gender.   
Men have higher rates of OUD, as do patients between ages 35 to 54 years, whites, and American 
Indians/Alaska natives.46 OUD is a clear predictor of overdose; therefore, it is important to look at all 
potential overdose factors for evaluating one’s overdose risk including socioeconomic status. For 
example, Medicaid enrollees are diagnosed with OUD at a rate of 8.7 per 1,000, over 10 times higher 
than populations who receive coverage under private insurance companies.47,48   
The opioid epidemic has a disproportionate impact on Medicaid enrollees. Medicaid enrollees are 
prescribed opioids at twice the rate of non-Medicaid enrollees.49,50 These prescribing practices among 
Medicaid enrollees have led to a three times higher risk of overdose compared to non-Medicaid 
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patients.49 Given the asymmetric impact of the opioid epidemic on Medicaid enrollees, it is especially 
important to study this vulnerable population to develop strategies to prevent overdose. 
In response to this disparity, Medicaid has implemented several national and statewide policies. Centers 
for Medicare and Medicaid Services (CMS) “best practice” policies for addressing prescription opioid 
overdose and misuse include pharmacy benefit management strategies such as reassessing preferred 
drug list (PDL) placement, introducing clinical criteria, prior authorization, step therapy, quantity limits, 
and implementing drug utilization review (DUR) processes.50,51 Some states have adopted new limits to 
the number of opioid pills that physicians can prescribe. 46 states have adopted quantity limits and 45 
states had adopted prior authorization targeted at opioid harm reduction.52 Medicaid is the single 
largest source of insurance for behavioral health services and OUD treatment, so improving and 
expanding treatment in this population is crucial.53  
Heroin is a highly addictive drug that is derived from the opium plant. Heroin was a popular pain 
treatment in the late 1880, but was quickly found to be addictive. Heroin was classified as a Schedule 1 
drug under the Controlled Substances Act of 1970, making it illegal to prescribe.54 Despite these barriers, 
heroin use continued to increase in the United States. The most common demographic of a heroin user 
switched from a young urban African-American male in the 1970s to a middle-aged white female from 
rural America.17 In the US, heroin use is the highest it has been in the last twenty years.55,56 Numerous 
studies indicate that prescription opioids have a gateway effect on subsequent heroin users, with 4 out 
5 heroin users stating that their opioid use began with prescription opioids.57-59  
Prescription opioid users have recently started shifting to heroin, which has a cheaper street value, 
higher purity, and is easier to obtain.60 Due in part to these factors, deaths due to heroin has been 
increasing precipitously in the last several years. In addition to the risk of overdose, IV drug use involving 
heroin has been implicated in many other medical conditions including human immunodeficiency virus 
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(HIV) and hepatitis C virus (HCV) infection. The relationship between heroin and prescription opioids 
emphasizes the importance that neither issue should be addressed in isolation.  
Fentanyl has played an increasing role in overdoses since 2013. Fentanyl is a synthetic opioid that is 50-
100X more powerful than morphine and 30-50X more powerful than heroin, making it an extremely 
potent opioid.61 Fentanyl can rapidly suppress respiration causing death more quickly than do other 
opioids. From 2012 through 2014, the number of reported deaths involving fentanyl more than doubled; 
from 2628 to 5544.62 The relatively low production cost of fentanyl and increasingly high death toll 
poses a challenging problem in efforts to combat the opioid epidemic. Fentanyl is often mixed with 
heroin as a combination product often without the user’s knowledge. Besides the role of opioids in 
overdose, there are also non-opioid medications taken in combination with opioids that has implications 
in overdoses.  
Benzodiazepines and opioids taken together increase the risk the overdose by a factor of 4.31 
Benzodiazepines are involved in 30% of drug overdoses involving opioids.63 Although the 
benzodiazepines effect of respiratory depression in the brain is mild, the concurrent use with opioids 
has the potential to increase and/or prolong the respiratory-depressant effect of opioids.64 The number 
of individuals prescribed both an opioid and a benzodiazepine increased by 41% between 2002 and 
2014.65 Approximately 50% of those co-prescriptions came from the same physician on the same day.66 
From 2004 to 2011, the rate of ED visits involving the non-medical use of both drug classes increases 
significantly and overdose deaths nearly tripled.65 The Food and Drug Administration (FDA) just released 
its strongest “box” warning on product labels that details the dangers of concomitant use of opioids and 
benzodiazepines. Evaluation of use of other potentially dangerous non-opioid medications like 
benzodiazepines is important part of addiction treatment. Although rates of spontaneous recovery from 
addiction and OUD are low, outcomes can be improved with medication-assisted treatment (MAT).  
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Mediation-Assisted Treatment 
The primary evidence-based treatment for OUD is MAT which includes FDA-approved medications 
methadone, buprenorphine and naltrexone. Behavioral counseling is also a crucial component of MAT. 
MAT significantly increases adherence to treatment and reduces illicit opioid use compared with non-
drug approaches. Patient with OUD receiving MAT as part of their addiction treatment are 75% less 
likely to overdose than those note receiving MAT.67 Unfortunately, these medications are markedly 
underutilized with fewer than half of OUD patients receiving MAT.68 Provider-level and policy-level 
barriers exist that restrict or severely limits patients from accessing MAT. Full integration of the 
continuum of services for OUD with the rest of health care is crucial.69  
Buprenorphine, a partial opioid agonist which can be given in outpatient clinics, was approved for the 
treatment of opioid addiction in 2002 by the Drug Addiction Treatment Act of 2000.70 Buprenorphine is 
becoming the gold standard for OUD treatment. As a treatment for OUD, buprenorphine decreases 
withdrawal, craving, and opioid use.26 Medical providers must obtain a waiver to prescribe 
buprenorphine, because prior to DATA 2000 such treatment was not permitted outside the traditional 
opioid treatment program (OTP) setting. Twelve years after buprenorphine approval, as of 2014 only 
2.2% of US physicians obtained the necessary waiver to prescribe buprenorphine. Most US counties 
(53.4%) do not have a single prescriber of medications to treat OUD.68 This equates to 30 million 
Americans living in counties that do not have a buprenorphine-waivered physician.71  
Fortunately, there has been a steady increase in the number of physicians obtaining the waiver. 
However, 40% of physicians with a waiver do no prescribe buprenorphine at all.45 Novice prescribers cite 
insufficient access to more-experienced prescribers and insufficient access to substance abuse 
counseling, a necessary component of buprenorphine treatment.72 The Comprehensive Addiction and 
Recovery Act (CARA) signed into law in July 2016, will extend buprenorphine privileges to nurse 
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practitioners (NPs) and physician assistants (PAs) starting in early 2017.73 Extending buprenorphine 
prescribing privileges to mid-level providers should help increase buprenorphine access to patients with 
OUD.  
Buprenorphine waivered physicians were limited to treating 30 patients with OUD in the first year, and 
then 100 in subsequent years. This restriction was a limiting factor, preventing some patients from 
receiving MAT. Restricting prescribers to treating a maximum of number of patients is unique to 
buprenorphine. Only a slight majority of waivered providers actually prescribe buprenorphine and most 
these providers do not prescribe to their maximum patient limit.74,75 This equates to the reality that only 
minority of waivered providers are providing most of the buprenorphine prescriptions.  
A recent survey found that 66% of addiction specialists reported that their patient demand for 
treatment exceeded the 100-patient prescribing limit.76 The irony of restricting buprenorphine, but not 
opioids, the very medication that has led to the need for buprenorphine is being remedied. Under new 
SAMHSA regulations, prescribers who have prescribed buprenorphine to 100 patients for at least one 
year can apply to increase their limit to 275 in July 2016. This is certainly a much-needed increase from 
the initial limit of 10 patients in 2002, however the number of number of people with OUD has also 
increased 125% from 2002.77  
Methadone is a potent synthetic opioid agonist that binds to the μ-opioid receptor, thereby reducing 
neuropathic pain. Methadone also blocks the opioid euphoric effect, thereby reducing the cravings and 
withdrawal symptoms caused by opioid use. Methadone has been used since 1972 to treat opioid 
addiction and is the most widely available pharmacotherapy for opioid addiction. Methadone 
significantly lowers illicit opioid use and opioid overdose.78 Although, methadone is an effective 
treatment of OUD, its use for the treatment of pain has been linked to thousands of overdose deaths 
each year.1 There was no difference found in OUD treatment outcomes between methadone and 
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buprenorphine.79 Significant access barriers to methadone include long waiting lists for treatment entry, 
limited geographic coverage, limited insurance coverage, and the requirement of daily visits at Opioid 
Treatment Programs. 
Naltrexone is semi-synthetic mu and kappa opioid receptor antagonist that blocks opioid addictive 
effects. Unlike methadone and buprenorphine, naltrexone is without intrinsic activity and poses minimal 
risk of abuse or diversion.80 There are no randomized double-blind controlled trials comparing all three 
medications. Individually, these medications have superior OUD treatment outcomes compared to non-
medication based therapies. Even when someone with OUD desires treatment, there are obstacles of 
starting treatment including the presence of psychological comorbidities and barriers to access. 
Access to Care 
MAT is widely available, however, there are systematic barriers including inadequate funding for 
treatment programs and lack of insurance coverage prevent people living with addiction from accessing 
these vital medications. Among public insurance plans, only 28 states currently cover all three FDA-
approved MAT medications.81 Although the ACA requires many insurers to cover addiction treatment 
benefits under the essential health benefit (EHB), it does not specify which benefits must be covered.82 
Many policies impose treatment-limiting prior authorization requirements, place arbitrary limits on 
medication dosage and length of treatment. Numerous private health insurance plans exclude coverage 
of methadone maintenance treatment, even though it is proven to be the effective treatment option for 
many people with OUD.83  
Access to MAT is challenging especially in rural areas. An important aspect of the opioid epidemic is the 
lack of treatment options for the millions of Americans living in rural communities. Overdose death rates 
are 45% higher in nonmetropolitan areas.2,84 One avenue to reduce the coverage gap in rural medicine is 
connecting physicians with patients remotely through telemedicine. Telemedicine can increase access to 
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addiction treatment service by removing the barriers of geography and stigma.85 The hub-and-spoke 
model is another initiative that connects community health centers and private practitioners with 
central, specialized substance abuse treatment programs after stabilizing the patient using MAT.  
The emergency department is becoming a battleground for patients with opioid addiction. In 2011, 
approximately 420,040 ED visits were related to use of opioids.86 For every opioid overdose, there are 10 
treatment admissions and 32 ED visits.87 Patients with OUD are increasingly seeking medical care in 
emergency departments not only for OUD-specific treatment, but also trauma, illness, and chronic 
medical conditions. Even though patients with OUD are seeking treatment in the ED, their treatment 
needs are not being met. Thousands of patients with OUD receive medical treatment to relieve opioid 
withdrawal only during brief detoxification admissions. Afterwards, these patients lose their tolerance 
to opioids, and are discharged with referrals to medication-free residential or outpatient care.88 Of those 
patients, 70-90% quickly relapse and face a high risk of overdose death.89  
Emergency departments have an opportunity to initiation treatment for patient with OUD who may not 
otherwise utilize healthcare. Emergency department initiated MAT referral to patients with OUD has 
already been shown to reduce illicit opioid use.90 Patients with OUD are more likely to receive MAT, and 
therefore reduce opioid use long-term if they are started on MAT in the emergency department.91 In 
addition, patients who initiated buprenorphine in the emergency department were more likely to 
remain in formal addiction treatment after 2 months compared to groups that were either referred for 
MAT.91  
For every fatal overdose, up to 30 nonfatal overdoses occur.92 Most long-term heroin users experience 
at least one nonfatal dose in their lifetime.93 People experienced non-fatal overdoses face high rates of 
chronic morbidity following injuries sustained during the overdose event such as renal failure and anoxic 
brain injury.94 Furthermore, non-fatal overdoses are a predictor for future fatal overdoses.20 Non-fatal 
12 
overdoses are likely underreported due to the increasing public availability of Naloxone, a medication 
which can reverse the effects of an opioid overdose.  
The preventable nature of these overdoses represents opportunities for health care providers to 
intervene to mitigate risks of future overdoses. Most fatal overdoses occur when the patient is not 
enrolled in a long-term, stable drug treatment.95 Potential responses include reassessing opioid 
prescribing and referring patients to addiction treatment. A study of commercially-insured patients 
indicated that high rates of prescription opioid use occurred after a nonfatal overdose suggesting that 
health systems could play a major role in informing opioid prescribers about patient’s addiction risk.96 
Understanding addiction risk could also lead to increased awareness and use of Naloxone.  
Naloxone is a rapid-acting μ opioid-receptor antagonist that reverses the effects of an opioid overdose 
by displacing the harmful opioid from the receptor. Naloxone has reversed thousands overdoses since 
its FDA approval in 1971 as an antidote for opioid overdose.97 Studies have shown that Naloxone could 
cut the overdose death rate by 50%.98 Many states have allowed people to obtain Naloxone without a 
prescription, removing an important barrier to receiving the life-saving medication. In addition, first 
responders including EMTs, police, and firefighters are now authorized to use Naloxone. However, other 
barriers remain including the cost of the medication and education of the proper use of the medication.  
Patients taking opioids for chronic pain who received information education and a prescription for 
Naloxone had 63% fewer opioid-related emergency department visits in one year than patients not 
receiving education and Naloxone.20 Naloxone is a safe, highly effective rescue medication and has no 
potential for abuse or dependency. Removing barriers for the use of Naloxone for opioid overdose is 
vital. Although MAT is effective is reducing opioid addiction, many patients do not complete addiction 
treatment regimens due to the chronic and relapsing nature of addiction.99  
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Pennsylvania Epidemiology 
The opioid epidemic has had a disproportionate effect on Pennsylvanians, with 3,505 overdose deaths in 
2015, a 30% increase from the previous year.100 This represents a 14-fold increase in the last 35 years.101 
Pennsylvania has the sixth highest overdose death rate in the country at 26.3 overdose deaths per 
100,000 compared to 16.3 deaths per 100,000 in the US.102  The death rate involving heroin is 5.6 per 
100,000 residents, 37% higher than the national average.2 Pennsylvania leads the nation in the number 
of drug overdoses in men ages 12-25.103 There have been several state-specific initiatives to reduce 
overdoses in Pennsylvania including changing emergency department guidelines.  
Limiting ED opioid prescriptions to seven days is a new guideline that is being discussed in several states 
across the country, including Pennsylvania.104 In addition, these guidelines also state that ED physicians 
may not write prescriptions for refills of opioids and ED physicians are required to refer individuals for 
treatment if the individual is believed to be at risk for substance abuse. These guidelines took effect on 
January 1st, 2017. These guidelines emphasize the importance of health care providers taking a more 
active role in the prevention and treatment of opioid addiction. Pennsylvania recently updated their 
prescription drug monitoring program (PDMP) to prevent prescription drug abuse in the state. 
Effective January 1, 2017 prescribers must query the PDMP each time a patient is prescribed an opioid 
or benzodiazepine by the prescriber. In addition, dispensing prescribers or pharmacies must now submit 
data to the PDMP no later than the close of the subsequent business day after dispensing the controlled 
substance. Across the country, implementation of PDMP has shown reduction in opioids dispensed and 
opioid-related mortality.105-110 
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Study 
 
Objective 
While MAT rates have increased over time, less is known about MAT use before or after overdoses, even 
in OUD patients. Thus, we compared prescription opioid and MAT use in patients before and after 
heroin or prescription opioid overdoses in a sample of Medicaid enrollees. 
Methods 
We collected 2008-2013 Medicaid enrollee claims data from the Pennsylvania Department of Human 
Services for all managed care (75%) and fee-for-service (25%) enrollees. Our sample included enrollees 
aged 12-64 years old with >6 months of continuous Medicaid enrollment before an overdose (with 
prescription opioids or heroin) that resulted in a Medicaid claim. We excluded enrollees who left 
Medicaid or died within 6 months of the overdose from the post-overdose measures to ensure complete 
follow-up but included them in the pre-overdose measures for completeness.  We used a logistic 
regression model with correlated data analysis to examine the differences in MAT and rates of 
prescription opioid use (any and cumulative days’ duration) pre-overdose and post-overdose and 
stratified analyses by the type of non-fatal overdose (opioid vs. heroin). All analyses were performed in 
SAS version 9.4 (SAS Institute, NC). This study was deemed exempt by the University of Pittsburgh 
Institutional Review Board. 
Results 
Among 3,009 enrollees who had a heroin overdose and 4,989 who had a prescription opioid overdose, 
most were <40 years old and white (Table 1). Among those with heroin overdose, 68.7% survived and 
were still enrolled in Medicaid 6 months post-overdose compared to 79.1% in the opioid group. Among 
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those who survived after the non-fatal overdose, opioid use did not change in the heroin group (40.6% 
pre and 39.7% post, P = 0.12, Figure 1) whereas enrollees in the opioid group were less likely to fill 
opioid prescriptions post-overdose (65.4% to 59.6% p < 0.001). Likewise, the percent of enrollees with 
>90 days duration of opioids did not change in the heroin group pre- to post-overdose (9.4% to 9.0%, P 
=0.07) but decreased in the opioid group (32.2% to 28.3%, P < 0.001). MAT increased after overdose in 
the heroin (28.7% to 33.0%, P < 0.001) and opioid group (from 13.6% to 15.1%, P = 0.001). Sensitivity 
analyses limiting the samples to only those diagnosed with OUD yielded similar findings. Among patients 
with OUD pre-overdose there was a significant decrease in greater than 180 opioid days supply post-
overdose compared to pre-overdose in the opioid group (17.7% pre and 13.0% post, p<0.001, Table 2). 
In contrast, there was no significant difference among greater than 180 opioid days’ supply post-
overdose in enrollees with OUD in the heroin group (3.6% pre and 3.8% post, P=0.91, Table 3). In 
enrollees with and without an OUD diagnosis there was significant decrease in greater than 180 opioid 
days’ supply post-overdose compared to pre-overdose in the opioid group (19.8% pre and 15.8% post, 
p<0.001, Table 4). In the heroin group, there was significant difference in greater than 180 opioid days 
supplied post-overdose compared to pre-overdose (4.3% pre and 4.0% post, P=0.96, Table 5). Among 
enrollees with an OUD diagnosis there was a decrease pre-overdose and post-overdose in both the 
opioid (52.5% pre and 44.9% post, p<0.001) and heroin (83.3% pre and 61.4% post, P<0.001) groups. 
There was no difference in benzodiazepine use post-overdose compared to pre-overdose in either the 
opioid group (46.9% pre and 45.2% post, P=0.10) and heroin group (38.3% pre and 36.6% post, P=0.20). 
There was no difference in muscle relaxant use post-overdose compared to pre-overdose in either the 
opioid group (26.2% pre and 24.7% post, P=0.11) and heroin group (15.0% pre and 15.8% post, P=0.48).  
Discussion  
MAT after overdoses increased in both the heroin and opioid groups. There was no change in opioid 
duration and use in the heroin group, whereas both measures declined in the opioid group. These 
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findings represent a missed opportunity to better engage enrollees with overdose sentinel events. 
Potential interventions to reduce future overdose events include trigger notifications to prescribers on 
patient overdose events to increase MAT and decrease potentially unsafe opioid prescribing. 
Furthermore, ED MAT initiation referral to patients with OUD has already been shown to reduce illicit 
opioid use.92 The opioid group showed a decrease in days’ supply of opioid, compared to the heroin 
which did show any change post-overdose. This difference could be related to better prescriber 
awareness of overdose due to prescription opioids compared to heroin. In addition, this reduction could 
be due to increased recognition of the dangers of prescribing a large amount of opioids as delineated by 
several opioid prescribing recommendations that have been released over the last several years. The 
fact that there was no change in benzodiazepine use or muscle relaxant use after overdose is troubling. 
Benzodiazepines and muscle relaxants in addition to opioids make of the “triple threat” of overdose risk. 
Further interventions should be targeted at decreasing benzodiazepine and muscle relaxant use 
including added warning labels to these medications and health system interventions such as 
prescription caps and prior authorization.  A limitation of this study is that actual use of prescription use 
is difficult to assess using claims data. 
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Appendix: Tables and Figures 
 
Table 1: Characteristics of Medicaid Enrollees with Opioid and Heroin Overdose Events 
                                            Heroin overdose Opioid overdose  
Characteristics Pre-overdose
1, 
N = 3,009 
Post-overdose2, 
N = 2,068 
Pre-overdose, 
N = 4,989 
Post-overdose, 
N = 3,945 
 N (%) N (%) N (%) N (%) 
Age     
12-17 41 (1.4) 37 (1.8) 277 (5.6) 251 (6.4) 
18-29 1514 (50.3) 981 (47.4) 1572 (31.5) 1210 (30.7) 
30-39 720 (23.9) 503 (24.3) 1186 (23.8) 950 (24.1) 
40-49 464 (15.4) 338 (16.3) 1083 (21.7) 880 (22.3) 
50-64 270 (9.0) 209 (10.1) 871 (17.5) 654 (16.6) 
Gender     
Female 1410 (46.9) 1001 (48.4) 2938 (58.9) 2431 (61.6) 
Race     
White 2467 (82.0) 1677 (81.1) 3777 (75.7) 2958 (75.0) 
Black  253 (8.4) 184 (8.9) 827 (16.6) 677 (17.2) 
Hispanic 234 (7.8) 164 (7.9) 278 (5.6) 220 (5.6) 
Other 55 (1.8) 43 (2.1) 107 (2.1) 90 (2.3) 
Type of Eligibility     
SSI 451 (15.0) 374 (18.1) 1228 (24.6) 1042 (26.4) 
TANF 635 (21.1) 464 (22.4) 1178 (23.6) 979 (24.8) 
General Assistance3 1088 (36.2) 635 (30.7) 1011 (20.3) 713 (18.1) 
Other 835 (27.8) 595 (28.8) 1572 (31.5) 1211 (30.7) 
Opioid Day Duration     
0 days (no fills) 1787 (59.4) 1246 (60.3) 1728 (34.6) 1592 (40.4) 
< 30 days 710 (23.6) 483 (23.4) 1111 (22.3) 814 (20.6) 
≥ 30 & < 90 days 228 (7.6) 152 (7.4) 545 (10.9) 422 (10.7) 
≥ 90 & < 180 days 151 (5.0) 104 (5.0) 624 (12.5) 501 (12.7) 
≥ 180 days 133 (4.4) 83 (4.0) 981 (19.7) 616 (15.6) 
OUD Diagnosis4 2505 (83.3) 1490 (72.1) 2614 (52.4) 1674 (42.4) 
Notes: 
1. Overdose evets were defined by ICD-9 codes 965.00, 965.01, 965.02, 965.09, E.850.0, E850.1, E.850.2. We 
including only the first overdose event for those with multiple overdoses. 
2. Post-overdose measures of opioid day duration and OUD diagnosis do not include those lost to follow-up 
due to disenrollment (n = 792, 15.9%) or death (n = 252, 5.1%) from Medicaid in the opioid overdose 
group or disenrollment (n = 808, 26.9%) or death (n = 133, 4.4%) from the heroin overdose group. 
3. General Assistance (GA) is state-funded assistance that provides money and other services for eligible 
individuals who do not meet the requirements of federally funded programs such as Temporary 
Assistance for Needy Families (TANF). 
4. Pre-overdose OUD diagnosis was recorded on an inpatient, outpatient or professional claim in the 6 
months before and including the overdose event. Post-overdose diagnoses were recorded >=1 day after 
the overdose event up to 6 months post-overdose to avoid including the overdose event in the definition 
of OUD.  
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Table 2: Medication use and medication-assisted treatment use pre vs. post-opioid overdose among 
those with OUD in pre-overdose period 
Outcomes Pre-overdose 
(n=2621) 
Post-overdose1 
(n=2015) 
 
Medication Use N (%) N (%) p-value 
Any opioid use 1663 (63.5) 1166 (57.9) <0.001 
Opioid Day Supply     
0 days (no fill) 963 (36.7) 855 (42.4)  
<30 days 595 (22.7) 429 (21.3)  
>= 30 & <90 days 295 (11.3) 231 (11.5) <0.001 
>=90 & < 180 days 305 (11.6) 238 (11.8)  
>= 180 days 463 (17.7) 262 (13.0)  
MAT use    
Methadone 413 (15.8) 321 (15.9) 0.87 
Buprenorphine 247 (9.4) 213 (10.6) 0.20 
Naltrexone 24 (0.9) 23 (1.1) 0.45 
Any MAT 653 (24.9) 528 (26.2) 0.32 
 
Table 3: Medication use and medication-assisted treatment use pre vs. post-heroin overdose among 
those with OUD in pre-overdose period  
Outcomes Pre-overdose 
(n=2242) 
Post-overdose1 
(n=1529) 
 
Medication Use N (%) N (%) p-value 
Any opioid use 910 (40.6) 617 (40.4) 0.88 
Opioid Day Supply     
0 days (no fill) 1339 (59.7) 916 (59.9)  
<30 days 549 (24.5) 368 (24.1)  
>= 30 & <90 days 166 (7.4) 121 (7.9) 0.91 
>=90 & < 180 days 108 (4.8) 66 (4.3)  
>= 180 days 80 (3.6) 58 (3.8)  
MAT use    
Methadone 257 (11.5) 214 (14.0) 0.02 
Buprenorphine 476 (21.1) 336 (22.0) 0.59 
Naltrexone 64 (2.9) 51 (3.3) 0.40 
Any MAT 730 (32.6) 549 (35.9) 0.03 
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Table 4: Medication use and medication-assisted treatment use pre vs. post-opioid overdose 
Outcomes Pre-overdose,  
N = 4,997 
Post-overdose1 
N = 3,952 
 
Medication Use N (%) N (%) p-value 
Opioid use 3279 (65.6) 2372 (60.0) <0.001 
Benzodiazepine use 2345 (46.9) 1786 (45.2) 0.10 
Muscle Relaxant use 1311 (26.2) 978 (24.7) 0.11 
Opioid + benzodiazepine + muscle 
relaxant use 
815 (16.3) 576 (14.6) 0.02 
Opioid Prescription Days Supply     
0 days (no fills) 1729 (34.6) 1592 (40.3)  
<30 days 1112 (22.2) 817 (20.7)  
>= 30 & <90 days 547 (11.0) 424 (10.7) <0.001 
>=90 & < 180 days 619 (12.4) 495 (12.5)  
>= 180 days 990 (19.8) 624 (15.8)  
OUD Diagnosis2 2621 (52.5) 1774 (44.9) <0.001 
MAT use    
Methadone 413 (8.3) 329 (8.3) 0.92 
Buprenorphine 269 (5.4) 265 (6.7) 0.009 
Naltrexone 29 (0.6) 31 (0.8) 0.24 
Any MAT3 680 (13.6) 595 (15.1) 0.05 
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Table 5: Medication use and medication-assisted treatment use pre vs. post-heroin overdose 
Outcomes Pre-overdose 
N = 2,693 
Post-overdose1 
N = 1,848 
 
Medication Use N (%) N (%) p-value 
Opioid use 1109 (41.2) 742 (40.2) 0.48 
Benzodiazepine use 1032 (38.3) 674 (36.5) 0.20 
Muscle Relaxant use 405 (15.0) 292 (15.8) 0.48 
Opioid + benzodiazepine + muscle 
relaxant use 
166 (6.2) 116 (6.3) 0.88 
Opioid Prescription Days Supply     
0 days (no fills) 1591 (59.1) 1110 (60.1)  
<30 days 655 (24.3) 438 (23.7)  
>= 30 & <90 days 197 (7.3) 136 (7.3) 0.96 
>=90 & < 180 days 134 (5.0) 90 (4.9)  
>= 180 days 116 (4.3) 74 (4.0)  
OUD Diagnosis2 2242 (83.3) 1134 (61.4) <0.001 
MAT use    
Methadone 257 (9.5) 233 (12.6) 0.001 
Buprenorphine 508 (18.9) 376 (20.3) 0.22 
Naltrexone 68 (2.5) 56 (3.0) 0.30 
Any MAT3 766 (28.4) 608 (32.9) 0.001 
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Figure 1: Medication use pre- and post-overdose (2008-2013)  
a We identified 3,009 enrollees in the heroin group pre-overdose and 2,068 post-overdose. We identified 4,989 enrollees in the opioid 
group pre-overdose and 3,945 post-overdose.  
b We identified overdose events by type (due to heroin or opioids) using ICD-9 codes (965.01, 965.00, 965.02, 965.09, E.850.1, E.850.2) in 
inpatient, outpatient, and professional claims. 
c Defined as any medication-assisted treatment (MAT). Some enrollees were prescribed > 1 MAT.  
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